Xovoltib 20mg (Afatinib Dimaleate)

Product Overview

Xovoltib 20mg is a drug that contains Afatinib Dimaleate is a potent oral tyrosine Kinase Inhibitor (TKI) specifically designed for the treatment of specific forms of non-small-cell lung cancer (NSCLC). Afatinib is a permanent blocker of the epidermal growth factor receptor (EGFR) family of tyrosine kinases. These frequently are overexpressed or mutated in cancerous cells. This leads to an inexplicably high rate of growth and expansion.

Xovoltib is recommended for patients who suffer from NSCLC that have particular EGFR mutations. It provides the possibility of a specific approach for cancer treatment that could increase the chances of success and stop the progression of the disease.

Active Ingredient

• Afatinib Dimaleate — 20 mg per tablet

Indications

The Xovoltib 20mg dosage is recommended to treat:

• Metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations (for example, exon 19 deletions, or Exon 21 L858R substitution mutations).
• Patients suffering from metastatic or locally advanced NSCLC who haven’t received previous EGFR TKI therapy.
• It is also a possibility for patients suffering from squamous NSCLC in the event of progression after chemotherapy with platinum (depending on the approval of your area).

Mechanism of Action

Afatinib can be described as an insoluble inhibitor of the ErbB family of receptors, which includes:

• EGFR (ErbB1)
• HER2 (ErbB2)
• HER4 (ErbB4)

Through covalent binding to the receptors mentioned above, afatinib inhibits the signaling pathways downstream that promote tumor cell growth and longevity. It causes the apoptosis (programmed death of cells) of tumor cells, which depend on abnormal ErbB signaling.

Dosage and Administration

• The suggested starting dosage should be 40 mg per day, but for those who are concerned about their tolerance, the daily dose of 20 mg, such as Xovoltib (20 mg), might be suggested.
• Tablets are best swallowed by mouth, accompanied by water or without food, in the same manner throughout the day.
• Adjustments to dosages may be required in response to adverse reactions.
• The treatment continues until the disease progresses or toxicity that is unacceptable is observed.
• The patient should be regularly monitored to determine the response and any side effects.

Precautions and Warnings

• Diarrhea, as well as the rash, is typical symptoms that need to be addressed promptly to avoid serious problems.
• Check for Interstitial Lung Disease (ILD)/pneumonitis, which may be life-threatening.
• Tests for liver function are important to monitor during treatment.
• Modifications or interruptions to the dose may be needed for extreme negative effects.
• Do not recommend during pregnancy. Effective contraception is recommended before and after the treatment.
• Beware of patients suffering from kidney or liver impairment.
• Do not use in conjunction with other strong CYP3A4 inhibitors or inducers because they can influence the afatinib level.

Side Effects

Common side effects include:

• Diarrhea
• Skin rash and acneiform dermatitis
• Stomatitis (mouth sores)
• Dry skin
• Nail effects (paronychia)
• Fatigue
• Decreased appetite

Not as frequent, but more serious adverse consequences:

• Interstitial lung disease (ILD)
• Hepatotoxicity
• Severe diarrhea leading to dehydration

Use in Special Populations

• Pregnancy: It is not recommended because of the risk of damage to the fetus.
• Lactation: The breastfeeding of infants should stop when you are undergoing the treatment.
• Pediatrics: The safety and effectiveness of this product have not been confirmed.
• Elderly: Not a specific dose adjustment; however, be sure to monitor the dose closely.

Storage Instructions

• Keep the temperature at a temperature below 30°C (86°F).
• Guard against light and moisture.
• Store tablets in their original containers until you need them.
• Be sure to keep away from children.

Patient Counseling Information

• Use Xovoltib in the same dose throughout the day, whether or not with or without eating.
• Avoid chewing or crushing tablets.
• Inform the authorities of extreme symptoms of skin irritation, diarrhea or breathing problems immediately.
• Make sure you take good care of your skin and ensure adequate hydration.
• Beware of sun exposure and use precautions to protect yourself from exposure to sunlight or the possibility of developing photosensitivity.
• Make sure to attend all medical appointments scheduled to be monitored.

Conclusion

Xovoltib 20mg (Afatinib Dimaleate) offers an effective therapeutic option targeted to those suffering from EGFR mutation-positive lung cancer. The irreversible inhibition of important growth factor receptors can slow the progression of cancer and enhance results for patients. The proper treatment of adverse effects, as well as treatment adherence, is crucial to maximizing advantages.